Arnatar Therapeutics Emerges with $52M to Develop First-in-Class RNA Therapy for Rare Genetic Disease
Key Insights
Arnatar Therapeutics (search) launched with $52 million in Series A funding to advance ART4 (search), a potentially first-in-class antisense oligonucleotide that increases JAG1 (search) protein expression to treat Alagille syndrome (search).
The FDA has granted ART4 (search) both orphan drug and rare pediatric disease designations for treating this rare genetic disorder that affects one in 70,000 newborns.
Preclinical studies demonstrate ART4 (search)'s ability to boost JAG1 (search) protein levels, restore bile duct development, and reduce liver damage markers in Alagille syndrome (search).
Arnatar Therapeutics (search) entered the biopharma arena on Monday with $52 million in Series A funding to advance what could be the first RNA-based therapy designed to increase rather than silence protein expression. The California-based startup is developing ART4 (search), an investigational antisense oligonucleotide targeting the rare genetic disease Alagille syndrome (search).
The FDA has already recognized ART4 (search)'s potential, granting the therapy both orphan drug and rare pediatric disease designations. This regulatory support underscores the significant unmet medical need in Alagille syndrome (search), a serious chronic disorder that affects one in every 70,000 newborns and impacts multiple organ systems including the heart and liver.
Novel Mechanism Addresses Root Cause
ART4 (search) represents a departure from conventional RNA therapeutics by targeting protein upregulation rather than silencing. The therapy is designed to increase expression of the JAG1 (search) protein, addressing the underlying pathophysiology of Alagille syndrome (search). According to Arnatar, approximately 95% of Alagille cases result from mutations in the JAG1 gene, leading to insufficient protein levels that compromise bile duct development and ultimately cause liver damage.
Preclinical studies have validated ART4 (search)'s mechanism of action, demonstrating the investigational therapy's ability to boost JAG1 (search) protein levels, help restore bile duct development, and reduce markers of liver damage. The company is currently conducting IND-enabling studies to support clinical development.
Dual RNA Platform Strategy
Beyond its lead program, Arnatar is also developing ART1 (search), an investigational siRNA therapy that employs the more traditional approach of target silencing. ART1 targets the AGT (search) protein, which plays a key role in blood pressure homeostasis, and is in early clinical development for cardiovascular disease (search).
This dual approach highlights Arnatar's strategy to explore both protein upregulation and silencing within the RNA therapeutics space, potentially expanding treatment options across different disease areas.
Strong Investor Support
The Series A funding round, closed in 2024, was led by Eight Roads (search) and 3E Bioventures (search), with participation from F-Prime Capital, New Alliance Capital, and Jifeng Ventures. Arnatar plans to use the capital primarily to advance ART4 (search)'s development through clinical trials.
The company's emergence follows a dynamic period in biotech launches, including Dispatch Bio's recent $216 million raise to develop CAR T therapies for solid tumors. These developments reflect continued investor interest in novel therapeutic modalities addressing areas of significant unmet medical need.